Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-08
2005-11-08
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266210, C514S266230, C514S266240, C514S266300, C514S266310, C433S208000, C433S208000, C433S208000, C433S208000
Reexamination Certificate
active
06962922
ABSTRACT:
A compound selected from those of formula (I):whereinW1represents O, S, or —NR3in which R3represents hydrogen, alkyl, OH or CN;W2represents a group selected from hydrogen, CF3, NH2, monoalkylamino, dialkylamino, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkylalkyl, heterocycle, these groups being optionally substituted,or W1and W2form together a group of formula —N═X4—W3— as defined in the description,X1, X2and X3represent N or C optionally substituted,n is 0 to 8,Z represents —CR12R13, wherein R12and R13are as defined in the description,A represents a ring system,the groups R2represent hydrogen or various chemical groups as defined in the description,q is 0 to 7;R1represents hydrogen, alkyl, alkenyl, alkynyl, or a ring system,and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.
REFERENCES:
patent: 3655679 (1972-04-01), Shen et al.
patent: 4818819 (1989-04-01), Taylor et al.
patent: 4902796 (1990-02-01), Taylor et al.
patent: 5389631 (1995-02-01), Claremon et al.
patent: 5521181 (1996-05-01), Meyer et al.
patent: 5646141 (1997-07-01), Varney et al.
patent: 5929097 (1999-07-01), Levin et al.
patent: 5948780 (1999-09-01), Peterson, Jr. et al.
patent: 6008243 (1999-12-01), Bender et al.
patent: 6225311 (2001-05-01), Levin et al.
patent: 2002/0151555 (2002-10-01), Barvian et al.
patent: 2002/0151558 (2002-10-01), Andrianjara et al.
patent: 2002/0156061 (2002-10-01), Barvian et al.
patent: 2002/0156069 (2002-10-01), Picard et al.
patent: 2002/0161000 (2002-10-01), Barvian et al.
patent: 2002/0193377 (2002-12-01), Andrianjara et al.
patent: 2003/0004172 (2003-01-01), Ilarter et al.
patent: 2003/0144274 (2003-07-01), Bunker et al.
patent: 2003/0216402 (2003-11-01), Gaudilliere et al.
patent: 2003/0220355 (2003-11-01), Gaudilliere et al.
patent: 2003/0229103 (2003-12-01), Weithmann et al.
patent: 2004/0006077 (2004-01-01), Gaudilliere et al.
patent: 2004/0038959 (2004-02-01), Bunker et al.
patent: 2004/0044000 (2004-03-01), Bunker et al.
patent: 2004/0063673 (2004-04-01), Johnson
patent: 0935963 (1999-08-01), None
patent: 1138680 (2001-10-01), None
patent: 10195063 (1998-07-01), None
patent: 9616046 (1996-05-01), None
patent: 9816514 (1998-04-01), None
patent: WO 00/09485 (2000-02-01), None
patent: 0035906 (2000-06-01), None
patent: 0040561 (2000-07-01), None
patent: 0044716 (2000-08-01), None
patent: 0045063 (2000-08-01), None
patent: WO 01/12611 (2001-02-01), None
patent: 0155133 (2001-08-01), None
patent: 0163244 (2001-08-01), None
patent: 0206513 (2002-01-01), None
patent: WO 02/34726 (2002-05-01), None
patent: WO 02/34753 (2002-05-01), None
patent: 02064080 (2002-08-01), None
patent: 02064547 (2002-08-01), None
patent: 02064568 (2002-08-01), None
patent: 02064571 (2002-08-01), None
patent: 02064572 (2002-08-01), None
patent: 02064578 (2002-08-01), None
patent: 02064595 (2002-08-01), None
patent: 02064598 (2002-08-01), None
patent: 02064599 (2002-08-01), None
patent: WO 2003/032999 (2003-04-01), None
patent: WO 2003/076417 (2003-09-01), None
patent: WO 2003/076417 (2003-09-01), None
patent: WO 2004/014378 (2004-02-01), None
patent: WO 2004/014379 (2004-02-01), None
patent: WO 2004/014384 (2004-02-01), None
patent: WO 2004/014921 (2004-02-01), None
patent: WO 2004/000322 (2004-12-01), None
E.C. Taylor, et al., “Pteridines. 51. A New and Unequivocal Route to C-6 Carbon-Substituted Pterins and Pteridines”, J. Org. Chem. 1987, 52:3997-4000.
E.C. Taylor, et al., “Convergent and Efficient Palladium-Effected Synthesis of 5,10-Dideaza-5,6,7,8-tetrahydrofolic Acid (DDATHF)”, J. Org. Chem. 1989, 52:3618-3624.
M.G. Natchus, et al., “Development of New Carboxylic Acid-Based MMP Inhibitors Derived from Functionalized Propargylglycines”, Journal of Medicinal Chemistry 2001, 44(7):1060-1071.
Derwent Publication Lt. Abstract No. 2001-514548; XP002213435.
A.B. Dyatkin et al., “The Solid Phase Synthesis of Complex Propargylamines Using the Combination of Sonogashira and Mannich Reactions”, Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL 1998, 39(22)3647-3650.
John Montana & Andrew Baxter, “The design of selective non-substrate-based matrix metalloproteinase inhibitors”, Current Opinion in Drug Discovery & Development 2000, 3(4):353-361.
Clark et al., “Matrix metalloproteinase inhibitors in the treatment of arthritis”, Current Opinion in Anti-inflammatory & Immunomodulatory Investigational Drugs 2000, 2(1):16-25.
Chen et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc. 2000, 122:9648-9664.
Wernicke, et al., “Cloning of Collagenase 3 from the Synovial Membrane and Its Expression in Rheumatoid Arthritis and Osteoarthritis”. J. Rheum., 1996; 23: 590-595.
Reboul, et al., “The New Collagenase-3. Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes”, J. Clin. Invest., 1996; 97: 2011-2019.
Freemont, et al., “In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage”, Ann. Rheum. Dis., 1999; 58: 357-365.
U.S. Appl. No. 10/071,032, filed Feb. 8, 2002, Dyer et al.
U.S. Appl. No. 10/634,489, filed Aug. 5, 2003, Roark.
Lisa A. Neuhold, et al., “Postnatal expression in hyaline cartilate of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice”, J. Clin. Invest., 2001: 107(1): 35-44.
Leif Dahlberg, et al., “Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (Matrix Metalloproteinase1)”, Arthritis & Rheum., 2000: 43(3): 673-682.
R. Clark Billinghurst, et al., “Comparison of the degradation of type II collagen and proteoglycan in nasal articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase”, Arthritis & Rheum., 2000; 43(3): 664-672.
Peter G. Mitchell, et al., “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., 1996; 97(3): 761-768.
R. Clark Billinghurst, et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”, J. Clin. Invest., 1997; 99(7); 1534-1545.
Nedjeljko Kujundzic, et al., “Synthesis of 8-Methyl-1,2,3,4-tetrahydropyrido-[3,4-d]pyrimidine-2,4-diones”. Coratica Chemica Acta, 1991: 64(4): 599-606.
Kosaku Hirota, et al., “Novel Synthesis of Pyrido[3,4-Id]pyrimidines, Pyrido[2,3-d]-pyrimidines, and Quinazolines Via Palladium-catalyazed Oxidative Coupling”, Heterocycles, 1994; 37(1): 563-570.
Gaudilliere Bernard
Jacobelli Henri
Picard Joseph Armand
Wilson Michael William
Ashbrook Charles W.
McKenzie Thomas C.
Pfizer Inc.
Purchase, Jr. Claude F.
Warner-Lambert Company LLC
LandOfFree
Alkynylated quinazoline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alkynylated quinazoline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkynylated quinazoline compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3458917